Understand the source comparison
DSIP Review 2026: Research vs Clinical Application Comparison
Stress neurobiology research 5–15 mcg/kg subcutaneous SC injection, intranasal (12–20 mcg/kg) Cortisol/corticosterone reduction, CRH mRNA expression 5–14 days HPA modulation is the primary mechanism. Sleep effects are downstream; models must have elevated base
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Stress neurobiology research
- 5–15 mcg/kg subcutaneous
- SC injection, intranasal (12–20 mcg/kg)
- Cortisol/corticosterone reduction, CRH mRNA expression
- 5–14 days
- HPA modulation is the primary mechanism. Sleep effects are downstream; models must have elevated baseline cortisol to show meaningful response
- Sleep architecture studies
- 7.5–10 mcg/kg subcutaneous
- SC injection, late afternoon (4–6 PM optimal)
- Delta wave percentage, total sleep time, REM latency
- 7–21 days
- DSIP increases delta sleep in stress-adapted subjects by 12–18% but has minimal effect in subjects with normal cortisol profiles
- Human clinical trials (investigational)
- 0.5–1.5 mg total dose
- SC injection or intranasal spray
- Subjective sleep quality scores, Pittsburgh Sleep Quality Index (PSQI)
- 4–8 weeks
- Subjective improvements reported in 60–70% of participants with chronic stress or insomnia; placebo response rate ~35% makes blinding critical
- Peptide stability testing
- N/A. Analytical only
- Lyophilized at −20°C, reconstituted at 2–8°C
- HPLC purity, mass spec confirmation, potency retention
- 24 months (lyophilized), 14 days (reconstituted)
- Proper storage maintains >98% purity; temperature excursions and light exposure are the most common causes of degradation